Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPC5 | Q9UL62 | 5/20 | 0.40 |
| ▸ | TRPC4 | Q9UBN4 | 2/20 | 0.37 |
| ▸ | HTR2A | P28223 | 5/20 | 0.36 |
| ▸ | HTR2C | P28335 | 5/20 | 0.36 |
| ▸ | HTR2B | P41595 | 5/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 8/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29329813 | 0.80 | TRPC5 (0.47) | TRPC5TRPC4HTR2AHTR2CHTR2B | |
| SCHEMBL21832182 | 0.80 | TRPC5 (0.43) | TRPC5TRPC4HTR2AHTR2CHTR2B | |
| SCHEMBL28567854 | 0.79 | TRPC5 (0.46) | TRPC5TRPC4SCN9A | |
| SCHEMBL21807302 | 0.78 | TRPC5 (0.48) | TRPC5TRPC4HTR2AHTR2CHTR2B | |
| SCHEMBL21807481 | 0.77 | TRPC5 (0.44) | TRPC5TRPC4SCN9A | |
| SCHEMBL21807225 | 0.77 | TRPC5 (0.55) | TRPC5TRPC4 | |
| SCHEMBL21807389 | 0.74 | TRPC5 (0.43) | TRPC5TRPC4SCN9ASLC6A2SLC6A4 | |
| SCHEMBL27124708 | 0.71 | TRPC5 (0.43) | TRPC5TRPC4 | |
| SCHEMBL21807664 | 0.71 | AURKA (0.39) | TRPC5TRPC4SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21807194 | 0.71 | HTR2C (0.41) | TRPC5HTR2AHTR2CHTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113939295-B | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2025-05-16 | — | — | CN | disclosed |
| EP-4414365-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2024-08-14 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| EP-3852533-B1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO INC (US) | 2024-02-28 | — | — | EP | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-05-19 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. | 2022-01-27 | — | — | US | disclosed |
| EP-3941475-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | Goldfinch Bio, Inc. (US) | 2022-01-26 | — | — | EP | disclosed |
| CN-113939295-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2022-01-14 | — | — | CN | disclosed |
| US-11046690-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2021-06-29 | — | — | US | disclosed |
| CN-112911935-A | Pyridazinones and methods of use thereof | 金翅雀生物公司 | 2021-06-04 | — | — | CN | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| WO-2020191056-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-09-24 | — | — | WO | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-09-10 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-10654850-B2 | Pyridazinones and methods of use thereof | GOLDFINCH BIO, INC. (US) | 2020-05-19 | — | — | US | disclosed |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GFB (ABC), LLC | 2020-04-02 | — | — | US | disclosed |
| WO-2020061162-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GOLDFINCH BIO, INC. (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024917-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885TRPC4 3512/4885HTR2A 948/4885 |
| US-20220152031-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | GLS, ATP6V1B1, PDXK | TRPC5 3626/4885TRPC4 4095/4885HTR2A 898/4885 |
| US-20200102301-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885TRPC4 3512/4885HTR2A 948/4885 |
| US-11046690-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | TRPC5 2486/4885TRPC4 3512/4885HTR2A 948/4885 |
| US-20200283437-A1 | PYRIDAZINONES AND METHODS OF USE THEREOF | ATP6V1B1, GLS, REN | TRPC5 2486/4885TRPC4 3512/4885HTR2A 948/4885 |
| US-10654850-B2 | Pyridazinones and methods of use thereof | ATP6V1B1, GLS, REN | TRPC5 2486/4885TRPC4 3512/4885HTR2A 948/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.